Today, the CMO of Amag Pharmaceuticals (AMAG), Julie Krop, bought shares of AMAG for $99.1K.
Following this transaction Julie Krop’s holding in the company was increased by 14.01% to a total of $799.3K. In addition to Julie Krop, 2 other AMAG executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Amag Pharmaceuticals has an average volume of 842K.
Based on 4 analyst ratings, the analyst consensus is Hold with an average price target of $13.00, reflecting a 39.3% upside.
The insider sentiment on Amag Pharmaceuticals has been positive according to 48 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia.
